ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/08/22
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer's Disease PsychosisBusiness Wire • 08/05/22
Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022Business Wire • 07/25/22
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACADPRNewsWire • 07/22/22
Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett SyndromeBusiness Wire • 07/18/22
Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress DisorderBusiness Wire • 07/18/22
Acadia's stock down 30% in premarket trading on Tuesday after last week's FDA committee voteMarket Watch • 06/21/22
Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer's Disease PsychosisBusiness Wire • 06/18/22
Acadia Pharmaceuticals stock halted for FDA panel to review treatment for hallucinations stemming from Alzheimer's disease psychosisMarket Watch • 06/17/22